RATIONALE: Accessorized pre-filled syringes (APFS) are functional and reliable for delivery of benralizumab subcutaneously (SC) in the clinic or at home, as demonstrated by the GREGALE study (NCT02417961).
were collected. Global assessment of improvement was determined by the documentation of the treating physician. Patients were excluded if they did not have 4 months of follow up. RESULTS: Twenty-one patients were identified. 46% were female and mean age was 57 years. Indication for mepolizumab was eosinophilic asthma in 20 patients and eosinophilic pneumonia in one patient. Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma were concurrent in 17 patients. At baseline, 14 patients were on daily oral corticosteroids (OCS). Combination ICS and LABA were prescribed for 13 patients and of these, 10 were on additional controller therapies. All OCS patients were able to decrease the dose of OCS during mepolizumab treatment. At 6 months the mean ACT increased from 14 (SD 5.56) at baseline to 20 (SD 4.74). FEV1 mean increased from 72% (SD 21.7) to 82% (SD 21.9) of predicted. Global assessment corroborated improvements in asthma, but little change in symptoms or signs related to CRSwNP. CONCLUSIONS: In a series of 21 patients treated with mepolizumab 85% of patients had concurrent CRS w/NP and eosinophilic asthma. Clinical improvements were seen in asthma control, however, no clear improvement was seen in CRSwNP.
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Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab Lisa Hickey 1 , Warner Carr 2 , and Margaret Garin 1 ; 1 Teva Branded Pharmaceutical Products R&D Inc., Malvern, PA, 2 Allergy & Asthma Associates of Southern California, Mission Viejo, CA. RATIONALE: Reslizumab, a humanized anti-interleukin-5 monoclonal antibody, improves asthma exacerbation rates, lung function, and patientreported outcomes in patients with uncontrolled eosinophilic asthma. Trends over 52 weeks of treatment in improvements in asthma control and quality of life based on the ACQ and AQLQ minimal important difference (MID) are hitherto unreported. METHODS: Data were pooled from two 52-week placebo (PBO)-controlled phase 3 trials of IV reslizumab (3mg/kg Q4W) (Castro, 2015) . ACQ-7 was measured every 4 weeks and AQLQ every 16 weeks from baseline. Reported response rates reflect proportions of patients achieving MID (0.5-point improvement) in each measure at each visit in each group. RESULTS: 953 patients were studied (reslizumab n5477; placebo n5476). 282 reslizumab-treated patients (60%) were ACQ-7 responders at Week 4 versus 231 (50%) placebo-treated patients (p50.001); mean treatment difference -0.219 (p<0.0001). Maximal ACQ-7 response rates occurred at Week 32: 328 (77%) reslizumab-treated patients and 280 (67%) placebo-treated patients (p50.001); mean treatment difference -0.228 (p<0.001). For AQLQ, 288 (66%) reslizumab-treated patients and 247 (57%) placebo-treated patients were responders at Week 16; mean treatment difference 0.210 (p50.0019). Maximal AQLQ response rates occurred at Week 52; 309 (73%) reslizumab-treated patients and 257 (63%) of placebo-treated patients; mean treatment difference 0.317 (p<0.0001). CONCLUSIONS: Reslizumab produced clinically meaningful improvements in asthma control and quality of life at the first measured timepoint. While ACQ response rates plateaued after 32 weeks, AQLQ response rate continued to rise throughout the treatment period. Quality of life benefits from anti-IL5 therapy may continue to increase throughout the first year of treatment.
